Potent and orally bioavailable GPR142 agonists as novel insulin secretagogues for the treatment of type 2 diabetes

ACS Medicinal Chemistry Letters

Volumn 4, Issue 8, 2013, Pages 790-794

  Toda, Narihiro ^a   Hao, Xiaolin ^b   Ogawa, Yasuyuki ^a   Oda, Kozo ^a   Yu, Ming ^b   Fu, Zice ^b   Chen, Yi ^b   Kim, Yongjae ^b   Lizarzaburu, Mike ^b   Lively, Sarah ^b   Lawlis, Shauna ^b   Murakoshi, Michiko ^a   Nara, Futoshi ^a   Watanabe, Nobuaki ^a   Reagan, Jeff D ^b   Tian, Hui ^b   Fu, Angela ^b   Motani, Alykhan ^b   Liu, Qingxiang ^b   Lin, Yi Jyun ^b   Zhuang, Run ^b   Xiong, Yumei ^b   Fan, Peter ^b   Medina, Julio ^b   Li, Leping ^b   Izumi, Masanori ^a   Okuyama, Ryo ^a   Shibuya, Satoshi ^a   more..

^a DAIICHI SANKYO CO   (Japan)

^b AMGEN INC   (United States)

Author keywords

agonist; diabetes; glucose lowering; GPR142; insulin secretagogue

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; GPR142 AGONIST; INSULIN DERIVATIVE; SITAGLIPTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; GLYCEMIC CONTROL; HAPLORHINI; HIGH THROUGHPUT SCREENING; IC 50; IN VIVO STUDY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT;

MUS;

EID: 84881430051     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400186z     Document Type: Article

References (15)

1. Defronzo, R. A. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes Diabetes 2009, 58, 773-795
2. Nazimek-Siewniak, B.; Moczulski, D.; Grzeszczak, W. J. Risk of macrovascular and microvascular complications in type 2 diabetes: results of longitudinal study design Diabetes Complications 2002, 16, 271
3. Randell, M. The role of sulfonylureas in the management of type 2 diabetes mellitus Drugs 2004, 64, 1339-1358
4. Burge, M. R.; Sood, V.; Sobhy, T. A.; Rassam, A. G.; Schade, D. S. Sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus: a review Diabetes, Obes. Metab. 1999, 1, 199-206
5. Drucker, D. J.; Nauck, M. A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2006, 368, 1696-1706
6. Bharate, S. B.; Nemmani, K. V.; Vishwakarma, R. A. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): An emerging target for type 2 diabetes Expert Opin. Ther. Pat. 2009, 19, 237-294
7. Ohishi, T.; Yoshida, S. The therapeutic potential of GPR119 agonists for type 2 diabetes Expert Opin. Invest. Drugs 2012, 21, 237-294
8. Xiong, Y.; Motani, A.; Reagan, J.; Gao, X.; Yang, H.; Ma, J.; Schwandner, R.; Zhang, Y.; Liu, Q.; Miao, L.; Luo, J.; Tian, H.; Chen, J.-L.; Murakoshi, M.; Nara, F.; Yeh, W.-C.; Cao, Z. Manuscript in preparation.
9. Lizarzabura, M.; Turcotte, S.; Du, X.; Duquette, J.; Fu, A.; Houze, J.; Li, L.; Liu, J.; Oda, K.; Okuyama, R.; Yu, M.; Reagan, J.; Medina, J. C. Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus Bioorg. Med. Chem. Lett. 2012, 22, 5942-5947
10. Du, X.; Kim, Y.-J.; Lai, S.; Chen, X.; Lizarzaburu, M.; Turcotte, S.; Fu, Z.; Liu, Q.; Zhang, Y.; Motani, A.; Oda, K.; Okuyama, R.; Nara, F.; Murakoshi, M.; Fu, A.; Reagan, J. D.; Fan, P.; Xiong, Y.; Shen, W.; Li, L.; Houze, J.; Medina, J. C. Phenylalanine derivatives as GPR142 agonists for the treatment of Type II diabetes Bioorg. Med. Chem. Lett. 2012, 22, 6218-6223
11. Ogawa, Y.; Okuyama, R.; Shibuya, S.; Toda, N.; Cao, Z.; Fu, Z.; Hao, X.; Kim, Y.; Li, L.; Lively, S.; Lizarzaburu, M.; Tian, H.; Yu, M. WO 2008/045484.
12. Waring, M. J. Lipophilicity in drug discovery Expert Opin. Drug Discovery 2010, 5, 235-248
13. Hu, Y.; Yang, S.; Shilliday, B.; Heyde, B. R.; Mandrell, K. M.; Robins, R. H.; Xie, J.; Reding, M. T.; Lai, Y.; Thompson, D. C. Novel metabolic bioactivation mechanism for a series of anti-inflammatory agents (2,5-diaminothiophene derivatives) mediated by cytochrome P450 enzymes Drug Metab. Dispos. 2010, 38, 1522-1531
14. Lluís, J.; Matheu, M.; Castillón, S. Stereoselective synthesis of 2′,3′-dideoxy-nucleosides via intramolecular glycosylation of phenyl 1-seleno-glycosides. Synthesis of 2′,3′- dideoxythymidine Tetrahedron Lett. 1998, 39, 1807-1810
15. Kim, D.; Wang, L.; Beconi, M.; Eiermann, G.; Fisher, M.; He, H.; Hickey, G.; Kowalchick, J.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M.; Patel, R.; Petrov, A.; Scapin, G.; Patel, S.; Roy, R.; Wu, J.; Wyvratt, M.; Zhang, B.; Zhu, L.; Thornberry, N.; Weber, A. (2 R)-4-oxo-4-[3-(Trifluoromethyl)-5,6- dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8 H)-yl]-1-(2,4,5-trifluorophenyl)butan- 2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J. Med. Chem. 2005, 48, 141-151